Zyloprim

Basic Zyloprim Information

• INN (International Nonproprietary Name): Allopurinol
• Brand Names Available In Canada (English): Zyloprim — tablets 100 mg and 300 mg.
• ATC Code: M04AA01 — M: Musculo-Skeletal System; 04: Antigout Preparations; AA: Preparations Inhibiting Uric Acid Production; 01: Allopurinol.
• Forms & Dosages: Oral tablets 100 mg (scored) and 300 mg (scored); powder for injection 500 mg vial.
• Manufacturers In Canada (English): Not specified.
• Registration Status In Canada (English): Not specified.
• OTC / Rx Classification: Prescription (Rx-only) in all markets; not available over the counter.

Critical Warnings & Restrictions In Canada

Priority Safety Guidance For Canadian Patients And Clinicians

Zyloprim (INN: allopurinol) is a prescription-only medicine in Canada and should not be started without a prescriber’s order.

Verify any known allergy to allopurinol or to tablet excipients before dispensing or starting therapy.

Assess renal and hepatic function with baseline labs before initiation and periodically during therapy.

Review concomitant medicines carefully, especially azathioprine and 6-mercaptopurine, which require specialist oversight or dose adjustment.

Warn patients about rare but life‑threatening severe cutaneous adverse reactions (SCARs), including Stevens–Johnson syndrome and toxic epidermal necrolysis.

Explain allopurinol hypersensitivity syndrome (AHS), sometimes described with fever, rash, eosinophilia and multi‑organ involvement, requires immediate cessation and urgent care.

Consider HLA-B*5801 testing in people with ancestry known to have higher allele prevalence (for example, some Asian populations) and discuss increased risk with Indigenous and other high‑risk groups.

Encourage good hydration and advise incremental titration rather than abrupt dose increases to reduce adverse events and improve tolerability.

Checklist For Pre‑Start Screening:

• Allergy history including previous rash to allopurinol.
• Baseline renal function (creatinine, eGFR) and hepatic panel.
• Medication review focusing on azathioprine, 6‑MP, ciclosporin, didanosine, and anticoagulants.
• Consider HLA‑B*5801 testing where clinically relevant.

Red Flags That Require Immediate Action:

• New widespread rash or mucosal lesions.
• Fever with skin symptoms.
• Facial or tongue swelling, or breathing difficulty.
• Progressive malaise, dark urine, jaundice, or declining kidney function.

Definitions:

• Allopurinol Hypersensitivity Syndrome (AHS): A multi‑system severe reaction that may include rash, fever, eosinophilia and organ dysfunction.
• Stevens–Johnson Syndrome / TEN: Severe mucocutaneous reactions with blistering and epidermal detachment that demand emergency care.

Q&A — “Can I Drive After Taking It In Canada?”

Usually yes, but avoid driving or operating machinery if you experience dizziness, drowsiness, or visual disturbance after a dose.

Report any new neurological symptoms to your pharmacist or prescriber promptly.

Usage Basics For Canadians

Names, Packaging And Legal Status In Canada

Patients commonly know the product as Zyloprim; the INN is allopurinol.

Tablets are commonly supplied as 100 mg and 300 mg scored tablets for oral use.

Some markets also have a 500 mg vial powder for injection but the oral tablet forms are the usual community supply.

In Canada, Zyloprim is prescription-only under Health Canada and product packs display a Drug Identification Number (DIN) assigned by Health Canada.

Record the DIN from packaging for benefits claims and for any adverse-event reporting.

• Dosage Forms: Tablets 100 mg and 300 mg; Injection 500 mg vial (powder for reconstitution).

• Brand vs Generic Options: Zyloprim brand and generic allopurinol formulations are available; discuss generic substitution with the patient.

1. DIN: Drug Identification Number used for reimbursement and tracking.
2. Rx‑Only: Prescription required for supply in Canada.

Note that Quebec and some national chains may use bilingual labelling or French‑forward packaging to meet provincial requirements.

Canadian Dosing Guide

Standard Regimens And Health Canada–Aligned Titration

Typical starting dose for chronic gout is 100 mg once daily with increases of about 100 mg every 1–2 weeks until target serum urate is achieved.

Maintenance doses commonly range from 200 mg to 300 mg once daily for most patients.

Titration may continue up to a clinical maximum of 800 mg/day, with split dosing recommended when total daily dose exceeds 300 mg.

In tumour‑lysis or acute oncology settings short‑term doses of 600–800 mg/day are used under specialist care.

For renal impairment start low; for example, patients with GFR <10 mL/min are commonly started at ≤100 mg/day with interval extension or dose reduction.

Children dosing is weight‑based at 10–20 mg/kg/day in divided doses up to a maximum of 400 mg/day for specific indications.

Baseline Labs Checklist:

• Serum urate.
• Serum creatinine and eGFR.
• Liver function tests.
• Complete blood count.

Q&A — “What If I Miss A Dose Under My Provincial Drug Plan?”

If you miss a dose, take it as soon as you remember unless it is close to the next scheduled dose and do not double up.

For coverage and refill questions under Ontario Drug Benefit, BC PharmaCare or RAMQ contact your pharmacy or plan to learn about early refill policies and emergency supply rules.

Interaction Chart (Canadian Context)

Key Drug And Food Interactions To Flag In Canada

The most important drug interaction is with azathioprine and mercaptopurine because xanthine oxidase inhibition increases active metabolites and risks myelosuppression.

Avoid co‑prescribing without specialist oversight and consider azathioprine dose reduction under close monitoring if combination is unavoidable.

Ciclosporin and didanosine have potential interactions that require monitoring and in some cases avoidance.

Allopurinol can alter warfarin response; monitor INR when starting, stopping or changing dose of allopurinol in patients on warfarin.

Thiazide diuretics may increase the risk of hypersensitivity reactions.

Alcohol increases gout flare risk and undermines urate‑lowering therapy objectives.

Substances To Avoid Or Reduce:

• Excess alcohol intake.
• Large purine‑rich meals that precipitate gout flares.

Monitoring Checklist For Interactions:

• Complete blood count for myelosuppression risk.
• Liver function tests where indicated.
• INR checks when on warfarin and any allopurinol dose change.

User Reports & Trends In Canada

What Canadian Patients And Community Pharmacists Report

Patients on forums and in pharmacy feedback commonly report good efficacy in chronic gout and consistent serum urate reductions with treatment.

Gastrointestinal complaints such as mild nausea and occasional diarrhea are frequently mentioned by patients.

Skin rash is a frequent concern among patients, prompting many to report immediately to their pharmacist or prescriber.

Community pharmacists note adherence challenges during symptom‑free periods and frequent patient questions about brand versus generic allopurinol.

Pharmacists in national chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu commonly counsel patients on titration, the importance of hydration and urgent care for rashes.

• Common Patient Sentiments: Efficacy for gout, worry about skin reactions, questions on brand vs generic.

Recommendation: Corroborate anecdotal trends with official pharmacovigilance reports such as Canada Vigilance for safety signal accuracy.

Access & Purchase Options

Where Canadians Can Legally Obtain Zyloprim

Zyloprim and generic allopurinol are dispensed in community pharmacies and hospital formularies across Canada with a valid prescription.

Large chains and independent pharmacies commonly stock 100 mg and 300 mg tablets for routine dispensing.

Online pharmacies operating in Canada must comply with provincial pharmacy regulations and some licensed services offer home delivery or in‑store pickup.

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ have varying coverage criteria based on age, income and indication.

Documentation Needed:

• Valid prescription from a licensed prescriber.
• DIN from packaging for benefits claims.
• Provincial health card or private insurance information for coverage checks.

Checklist For Confirming Legitimate Online Pharmacies:

• Registered with the provincial college of pharmacy.
• Clear contact details and physical pharmacy address.
• Licensed pharmacist available for counselling.

In our online pharmacy, zyloprim is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Mechanism & Pharmacology

Patient‑Friendly Explanation Plus Clinical Terms

Allopurinol is a xanthine oxidase inhibitor that decreases the production of uric acid by blocking the enzyme that converts xanthines to uric acid.

Chronic therapy lowers serum urate and reduces the frequency of gout flares and the risk of uric acid kidney stones.

The active metabolite oxypurinol has a long half‑life and is excreted primarily by the kidneys, which is why dose adjustments are needed in renal impairment.

• INN: Allopurinol.
• ATC: M04AA01.
• Mechanism: Xanthine oxidase inhibition reduces uric acid formation.

Key Pharmacokinetic Points:

• Oral bioavailability is adequate for systemic effect using tablets.
• Oxypurinol is the major active metabolite with prolonged duration of action.
• Renal clearance predominates, so renal impairment prolongs exposure.

Suggested Patient Handout Visual: A simple infographic showing inhibited enzyme (xanthine oxidase), reduced uric acid production and gradual flare reduction over months.

Indications & Off‑Label Uses In Canada

Health Canada‑Approved And Common Off‑Label Practices

Approved primary indications include chronic gout and management of hyperuricemia where clinically warranted.

Short‑term higher dosing is used in tumour‑lysis syndrome and acute oncology settings to prevent uric acid nephropathy under specialist supervision.

Common off‑label practices include prevention of recurrent calcium oxalate kidney stones at lower doses and selected metabolic disorders managed by specialists.

Checklist For Indication‑Specific Monitoring:

• Oncology/TLS: daily uric acid and renal function as directed.
• Gout: periodic serum urate to target levels and routine safety labs.

Remember that Zyloprim/allopurinol remains a prescription-only medicine and DIN documentation should be retained for reimbursement and reporting purposes.

Key Clinical Findings

Recent Canadian And International Evidence (2022–2025) And Safety Monitoring

Allopurinol remains first‑line for urate lowering with consistent efficacy in lowering serum urate and reducing gout flares when combined with appropriate prophylaxis such as colchicine or low‑dose NSAIDs.

Recent trials and observational data through 2025 continue to evaluate allopurinol versus febuxostat for comparative cardiovascular safety, with ongoing surveillance.

Health Canada undertakes routine post‑market safety monitoring and encourages reporting of adverse events to Canada Vigilance.

Severe hypersensitivity such as AHS remains rare but very serious, and early detection is essential to prevent morbidity and mortality.

• Key Endpoints: Serum urate reduction, flare frequency reduction, adverse event incidence.

Suggested Short Trial Summary Table (Examples To Be Filled With Specific Trial Names As Needed):

Clinicians should encourage reporting of suspected serious adverse events to national pharmacovigilance systems for signal detection and patient safety.

Alternatives Matrix

Comparable Medicines With DINs In Canada And Pros/Cons

Checklist For Switching Agents:

• Confirm indication and reason for switch (intolerance, refractory disease).
• Obtain baseline labs (renal, hepatic, CBC, urate).
• Refer to or consult a specialist for complex cases or high doses.

Common Questions From Canadian Patients

Can I stop during a flare?

No — do not discontinue established allopurinol during an acute gout attack without your prescriber’s advice, as stopping may prolong flares.

Will it interact with my warfarin?

Potentially — monitor INR when starting, stopping or changing dose of allopurinol and adjust warfarin as required.

Is genetic testing needed?

Consider HLA‑B*5801 testing in people with ancestry associated with higher risk; discuss testing with the prescriber.

How long until I feel benefits?

Serum urate lowering is measurable within weeks but meaningful reduction in flare frequency may take months of stable therapy and titration to target.

When To Contact Care:

• Any rash or fever while on therapy.
• New kidney pain, reduced urine output or jaundice.
• Unusual bleeding or bruising while on anticoagulants.

Coverage & Purchase Comparison Table

Provincial Plans, Typical Patient Cost And Access Steps

Step‑By‑Step Purchase Checklist For Patients:

1. Obtain a valid prescription from your prescriber.
2. Confirm the DIN on the dispensed pack for claims.
3. Check your provincial plan for coverage and copay details.
4. Ask the pharmacist for generic options and a cost estimate.
5. Request samples, blister packs or emergency supply if needed.

Registration & Regulation

Health Canada Approval, DIN And Labelling Requirements

Zyloprim/allopurinol is licensed as a prescription medicine and market packs carry a Health Canada Drug Identification Number (DIN) that should be recorded for reimbursement and reporting.

Labelling must meet federal and provincial standards, and Quebec labelling rules often require bilingual or French‑forward information on packs.

Patients and clinicians are encouraged to report adverse events to Canada Vigilance so Health Canada can monitor safety signals.

• DIN: Drug Identification Number used to track marketed medicines.
• NOC: Notice of Compliance is a regulatory term related to market authorizations.

Reporting Steps For Adverse Events:

• Document product name, DIN and batch number if possible.
• Report to Canada Vigilance online or by phone.
• Notify the patient’s provincial college of pharmacy for practice issues if relevant.

Storage & Handling

Practical Canadian Household And Pharmacy Guidance

Store Zyloprim at 20–25°C (68–77°F) and protect it from moisture and excessive heat.

Do not refrigerate standard oral tablets and keep them in the original container away from children and pets.

Pharmacies should use child‑resistant packaging where required and provide bilingual patient information upon request.

Hospitals handling IV powder (500 mg vials) must follow reconstitution protocols and safe‑handling procedures in oncology settings with time‑limited use after preparation.

Home Storage Checklist:

• Keep tablets in original container with label and DIN visible.
• Store at room temperature within recommended range.
• Keep out of reach of children and pets.

Guidelines For Proper Use

Pharmacist And Provincial Health Authority Recommendations

Perform a baseline assessment including allergy history, renal and hepatic labs, CBC and serum urate before initiating therapy.

Provide patient education that covers dose titration, the advice not to start therapy during an acute flare unless directed, the importance of hydration, and how to recognise early signs of severe reactions.

Follow‑Up Schedule: check labs 2–4 weeks after any dose change and then periodically based on clinical judgment.

Refer promptly for suspected AHS, severe renal failure or oncology tumour‑lysis syndrome.

Document the DIN on insurance claims and counsel on switching to generics when cost is a barrier.

• Pharmacist Counselling Checklist: baseline labs, titration plan, rash warning, hydration and adherence tips.
• Patient Handout Template Suggestions: dosing schedule, when to seek urgent care, contact numbers.

Action Flowchart For Suspected Severe Reactions:

• Stop allopurinol immediately.
• Refer to emergency department if rash is severe, with fever, mucosal involvement or systemic signs.
• Report the event to Canada Vigilance and document product details (DIN, batch if available).

Delivery Across Canada (English)